However, they are also possible therapeutic agents due to their potentially beneficial physiological effects. The angiotensin receptor–neprilysin inhibitor, sacubitril/valsartan, simultaneously ...
Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival therapies ...
The initial share sale of Senores Pharmaceuticals Ltd got subscribed 1.78 times on Friday, the first day of bidding. The Initial Public Offer (IPO) received bids for 1,51,51,550 shares against ...